Langerhans Cell Histiocytosis Involving the Thymus and Heart With Simultaneous Thymoma: A Case Report

Ting Ji†, Yuxia Zhong† and Deyun Cheng*

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Sichuan, China

Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal expansion of CD1a+/CD207+ cells in lesions. The most frequent sites involved are bone and, less commonly, lymph nodes, lungs, and skin. The thymus or heart is rarely involved with LCH. In this case, we present a 73-year-old woman with a mediastinal mass. Histopathology after thymectomy identified this mass as type AB thymoma; notably, subsequent immunohistochemical tests showed lesions of LCH scattered in the region of thymoma. 18-Fluorodeoxyglucose PET/CT (18-FDG-PET/CT) was performed to make an overall assessment of the extent of this disease, which demonstrated suspicious cardiac involvement of LCH. This report highlights the importance of differentiating abnormalities of the thymus or mediastinal mass from LCH and the necessity of comprehensive evaluation for patients with LCH.

Keywords: Langerhans cell histiocytosis, thymoma, thymus, heart, 18FDG-PET/CT

INTRODUCTION

Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal expansion of CD1a+/CD207+ cells, which often affects children and young adults (1). Thymoma, as the most common neoplasm in the anterior mediastinum, originates from epithelial cells in the thymus regardless of the presence or abundance of lymphoid component (2). It is extremely rare for two lesions of LCH and thymoma to occur in the same organ. Herein, we present a 73-year-old woman diagnosed with thymic LCH concurrent with type AB thymoma after thymectomy, with suspicious cardiac involvement of LCH demonstrated by 18-fluorodeoxyglucose PET/CT (18FDG-PET/CT). We believe that LCH should be included in the differential diagnosis of thymic abnormalities or mediastinal masses.

CASE PRESENTATION

A 73-year-old woman presented with chest tightness without evidence of myasthenia gravis and other complaints, such as fever, weight loss, pain, mass, skin lesion, and cough. She had no previous history of carcinoma or other comorbidities. Physical examination showed no abnormal signs. Her blood tests revealed no apparent abnormalities, including blood cell count, renal and liver function, and tumor markers (NSE, CYFRA21-1, CA15-3, CA19-9, and CA12-5). Chest CT showed an
irregular mass (51 mm × 35 mm) in the anterior mediastinum, with inhomogeneous enhancement on contrast-enhanced CT (Figure 1). A mediastinal tumor was highly suspected, and a biopsy was considered. After the physician communicated with this patient and her family, the patient had chosen direct thymectomy, not biopsy. Histopathology identified this mass as a type AB thymoma composed of lymphocyte-poor areas and lymphocyte-rich areas at low magnification. Small nodules of mononuclear cells and eosinophils were surrounded by lesions of thymoma, and immunohistochemical tests showed that these nodules were positive for S100, CD1a, and Langerin (Figure 2). The genomic analysis revealed no BRAF V600E mutation. Therefore, thymic LCH co-occurrence with type AB thymoma was considered. This patient also received radiotherapy after thymectomy (GTV5500cGy/25f, CTV5000cGy/25f). ¹⁸F-FDG-PET/CT was performed (Figure 3) and showed abnormal hypermetabolic regions in the chest, left femur, and right thigh, with the following maximum standardized uptake value (SUVmax): surgery-related changes of the sternum, 4.08; right atrial appendage, 7.08; a round mass with a size of 37 mm × 31 mm at the right upper thigh, 3.20; and left upper femur, 3.98. The patient underwent a biopsy for the mass of the right upper thigh in another hospital, of which immunohistochemical tests also proved the involvement of LCH. We could not be able to...
define the nature of lesions in the left upper femur and right atrial appendage because of difficulty in the biopsy. Eighteen months after thymectomy, there were no signs of recurrence on the chest contrast-enhanced CT, and the mass of the right upper thigh remains the same size. She also did not complain of symptoms of heart failure and bony pain.

**DISCUSSION**

The annual incidence of LCH is 5–9 cases per million in children older than 15 years and 1 case per million in patients older than 15 years (3). Thymoma is also a rare tumor of the mediastinum with an annual age-adjusted incidence of 0.9–2.3 cases per million (2). Therefore, thymoma and LCH rarely occur in the same organ.

LCH commonly affects the bone (80%), skin (33%), pituitary gland (25%), and lungs (15%) (3). The thymus is rarely involved (4). A retrospective study reported that 1.4% of pediatric LCH cases were found to have thymic involvement (5). However, data about thymic LCH in adults are lacking. Patients with thymic LCH could be asymptomatic; some patients are accidentally diagnosed by imaging examination, and others have undergone thymectomy during cardiothoracic surgery and were identified as thymic LCH by pathology (4, 6, 7). In addition, adults suffering from thymic LCH can also present with myasthenia gravis (4), which did not occur in our case. Previous literature had demonstrated the status of thymic LCH combined with lymphoid hyperplasia but no features of thymoma (8).
Researchers previously suggested routine imaging screening of the thymus in patients with LCH, especially in young children (5). To some degree, this abnormality of the thymus promotes early diagnosis in our case. We recommend routine screening of the biomarkers of LCH in thymic samples to investigate the presence of LCH.

Cardiac lesions are exceedingly rare in patients with LCH (9). There are no available data for the prevalence of cardiac involvement of LCH. Four case reports have shown the infiltration of the septum (10) and pericardium (11–13) by LCH. In our case, the hypermetabolic lesions in the right atrial appendage and left proximal femur demonstrated by 18F-FDG PET/CT were considered neoplastic changes. Due to the high risk of cardiac biopsy, we did not perform it on this patient. Based on the pathological identification of LCH in two regions for this patient, we highly suspect that the hypermetabolic lesions of the heart and femur were caused by LCH. It is true that we must consider the possibility of mixed LCH and Erdheim-Chester disease (ECD) when a patient with LCH has suspicious cardiac lesions (9). However, pericardial infiltration and effusion, sometimes complicated by cardiac tamponade, and pseudotumor of the right atrioventricular groove are the most common regions of cardiac involvement with ECD (9), which is not in line with our case. Due to the steel wire retention sutures in the chest during thoracotomy, cardiac magnetic resonance to help us define the nature of the cardiac lesion in this case cannot be performed on this patient. In most cases, the diagnosis and evaluation of LCH are challenging and delayed because clinical findings are non-specific and complicated. Late diagnosis and assessment could exacerbate LCH and lead to sequelae, such as disability and malformation associated with pathological fracture and growth retardation caused by the progression of LCH in the pituitary and even death (1). Besides, initial evaluation and diagnosis of LCH depend on full-body screening, and all lesions are FDG-avid (9, 14). Therefore 18F-FDG PET/CT could be a very useful tool to make a comprehensive evaluation in patients with LCH, guiding therapy for this disease (14, 15).

Currently, although treatment of LCH is not well established, which depends on lesions’ location and number, therapy strategies have been generally agreed upon (1, 16). Single-system lesion confined to only one single site needs local medication, curettage, or observation, such as skin and bone lesion (17). Multiple lesions in single-system LCH (SS-LCH) or multisystem LCH (MS-LCH) require systematic chemotherapy (1, 16). Along with the discovery of the mutated MAPK pathway in the pathogenesis of LCH, targeted therapy by BRAF or MEK inhibitors has become a novel therapeutic strategy for patients with LCH (18). Timely and proper treatment, which prevents the invasion of disease into risky organs (bone marrow, liver, and spleen), could promote a good prognosis (1, 16).

In conclusion, we report an “incidental” thymic LCH combined with thymoma in an old woman with highly suspicious cardiac involvement of LCH and emphasize the necessity of differentiating abnormalities of the thymus from LCH and comprehensive evaluation for patients with LCH, if possible, by PET/CT.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the West China Hospital of Sichuan University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

All authors have made a significant contribution to this paper. TJ and YZ drafted the manuscript. DC revised the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

The authors thank the patient and her family.

REFERENCES

1. Rodriguez-Galindo C, Allen CE. Langerhans Cell Histiocytosis. Blood (2020) 135:1319–31. doi: 10.1182/blood.201900934
2. Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and Thymic Carcinomas. Arch Pathol Lab Med (2017) 141:113–23. doi: 10.1001/archpathlabmed.2016.2003
3. Histoctyes: Emerging Neoplasia Behind Inflammation. Lancet Oncol (2017) 18:113–25. doi: 10.1016/S1470-4247(17)30031-1
4. Lee BH, George S, Kutok JL. Langerhans Cell Histiocytosis Involving the Thymus. A Case Report and Review of the Literature. Arch Pathol Lab Med (2003) 127:294–7. doi: 10.5858/rpc.2003-127-e294-LCHITT
5. Lakatos K, Herbrüggen H, Pötschger U, Prosch H, Minkov M. Radiological Features of Thymic Langerhans Cell Histiocytosis. Pediatr Blood Cancer (2013) 60:143–5. doi: 10.1002/pbc.24640
6. de Montjoye L, Dano H, Marot L, Tennstedt D, Brichard B, Van Eckhout P, et al. Langerhans Cell Histiocytosis Involving the Skin and the Thymus. Eur J Dermatol (2015) 25:82–3. doi: 10.1684/ejd.2014.2465
7. Novak L, Castro CY, Litsinsky CM. Multiple Langerhans Cell Nodules in an Incidental Thymectomy. Arch Pathol Lab Med (2003) 127:218–20. doi: 10.5858/2003-127-218-MLCNIA
8. Pescarmona E, Rendina EA, Ricci C, Baroni CD. Histiocytosis X and Lymphoid Follicular Hyperplasia of the Thymus in Myasthenia Gravis. Histopathology (1989) 14:465–70. doi: 10.1111/j.1365-2559.1989.tb02182.x
9. Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, et al. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc (2019) 94:2054–71. doi: 10.1016/j.mayocp.2019.02.023

10. Schreiber J, Waldburg N. FDG-PET/CT in Pulmonary and Cardiac Langerhans' Cell Histiocytosis and Metastatic Non-Small-Cell Lung Cancer. Nucl Med Biol (2012) 39:1173–4. doi: 10.1016/j.nucmedbio.2012.05.012

11. Pickens PV, Rosenhein M. Histiocytosis X With Pericardial Effusion. JAMA (1981) 246:1810–1. doi: 10.1001/jama.246.16.1810

12. Bagri NK, Yadav DK, Agarwal S, Aier T, Gupta V. Pericardial Effusion in Children: Experience From Tertiary Care Center in Northern India. Indian Pediatr (2014) 51:211–3. doi: 10.1007/s13312-014-0378-z

13. Gholami N. Pericardial Effusion in Langerhans Cell Histiocytosis: A Case Report. Iran Red Crescent Med J (2016) 18:25604. doi: 10.5812/ircmj.25604

14. Huynh KN, Nguyen BD. Histiocytosis and Neoplasms of Macrophage-Dendritic Cell Lineages: Multimodality Imaging With Emphasis on PET/CT. Radiographics (2021) 41:576–94. doi: 10.1148/rg.2021200096

15. Blumer SL, Scalcione LR, Ring BN, Johnson R, Motroni B, Katz DS, et al. Cutaneous and Subcutaneous Imaging on FDG-PET: Benign and Malignant Findings. Clin Nucl Med (2009) 34:675–83. doi: 10.1097/RLU.0b013e3181b53845

16. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med (2018) 379(9):856–68. doi: 10.1056/NEJMra1607548

17. Kobayashi M, Tojo A. Langerhans Cell Histiocytosis in Adults: Advances in Pathophysiology and Treatment. Cancer Sci (2018) 109(12):3707–13. doi: 10.1111/cas.13817

18. Diamond EL, Subbiah V, Lockhart ACBlay JY, Puzanov I, Chau L, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-Label VE-BASKET Study. JAMA Oncol (2018) 4(3):384–8. doi: 10.1001/jamaoncol.2017.5029

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ji, Zhong and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.